AMMON-OHE模型的开发与验证:预测肝硬化门诊患者发生显性肝性脑病的风险
这项观察性前瞻性研究纳入三个肝病中心426例无显性肝性脑病(OHE)史的肝硬化门诊患者,随访中位2.5年,评估心理测量或心理物理测试及血氨对后续OHE的预测价值,并开发AMMON-OHE模型;该模型(性别、糖尿病、白蛋白、肌酐、血氨/正常上限)在两个外部验证队列中预测首发OHE的C指数分别为0.844和0.728。
要点
- 心理测量肝性脑病评分(PHES)异常合并血氨/正常上限(AMM-ULN)高者发生OHE风险最高,风险比4.4(95%CI 2.4-8.1;P<0.001)。
- 多变量分析中仅AMM-ULN(而非PHES或临界闪烁频率CFF)是OHE发生的独立预测因子,风险比1.4(95%CI 1.1-1.9;P=0.015)。
- AMMON-OHE模型(性别、糖尿病、白蛋白、肌酐、AMM-ULN)在两个外部验证队列中预测首发OHE的C指数分别为0.844和0.728。
核心结论
- 研究开发并验证了AMMON-OHE模型,该模型包含易获得的临床和生化变量,可用于识别发生首发OHE风险最高的肝硬化门诊患者。
- AMMON-OHE模型在预测肝硬化门诊患者首发OHE方面优于PHES和CFF。
研究设计与样本
- 观察性前瞻性研究,纳入三个肝病中心426例无既往OHE的肝硬化门诊患者,随访中位2.5年。
- 采用多变量脆弱竞争风险和随机生存森林分析预测未来OHE并开发AMMON-OHE模型。
- 外部验证使用两个独立中心共267例和381例患者。
主要发现
- 按PHES或CFF及血氨分层,至OHE发生时间存在显著差异(log-rank P<0.001)。
- PHES异常合并AMM-ULN高者风险最高,与PHES正常且AMM-ULN正常者相比,风险比4.4(95%CI 2.4-8.1;P<0.001)。
- 多变量分析中,AMM-ULN是OHE发生的独立预测因子(风险比1.4;95%CI 1.1-1.9;P=0.015),而PHES或CFF不是。
- AMMON-OHE模型(性别、糖尿病、白蛋白、肌酐、AMM-ULN)在两个外部验证队列中预测首发OHE的C指数分别为0.844和0.728。
关键数值与推荐
- PHES<-4或CFF<39定义为异常。
- 血氨以各参考实验室正常上限进行标准化(AMM-ULN)。
临床怎么用
- AMMON-OHE模型已在线提供,可供临床使用。
- 模型包含性别、糖尿病、白蛋白、肌酐和AMM-ULN,用于识别首发OHE高危的肝硬化门诊患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Neuropsychological and psychophysical tests are recommended to assess the risk of overt hepatic encephalopathy (OHE), but their accuracy is limited. Hyperammonaemia is central in the pathogenesis of OHE, but its predictive utility is unknown. In this study, we aimed to determine the role of neuropsychological or psychophysical tests and ammonia, and to develop a model (AMMON-OHE) to stratify the risk of subsequent OHE development in outpatients with cirrhosis. METHODS: This observational, prospective study included 426 outpatients without previous OHE from three liver units followed for a median of 2.5 years. Psychometric hepatic encephalopathy score (PHES) <-4 or critical flicker frequency (CFF) <39 was considered abnormal. Ammonia was normalized to upper limit of normal (AMM-ULN) at the respective reference laboratory. Multivariable frailty competing risk and random survival forest analyses were performed to predict future OHE and to develop the AMMON-OHE model. External validation was carried out using 267 and 381 patients from two independent units. RESULTS: Significant differences were found in time-to-OHE (log-rank p <0.001) according to PHES or CFF and ammonia, with the highest risk in patients with abnormal PHES plus high AMM-ULN (hazard ratio 4.4; 95% CI 2.4-8.1; p <0.001 compared with normal PHES and AMM-ULN). On multivariable analysis, AMM-ULN but not PHES or CFF was an independent predictor of the development of OHE (hazard ratio 1.4; 95% CI 1.1-1.9; p = 0.015). The AMMON-OHE model (sex, diabetes, albumin, creatinine and AMM-ULN) showed a C-index of 0.844 and 0.728 for the prediction of a first episode of OHE in two external validation cohorts. CONCLUSIONS: In this study, we developed and validated the AMMON-OHE model, comprising readily available clinical and biochemical variables that can be used to identify outpatients at the highest risk of developing a first episode of OHE. IMPACT AND IMPLICATIONS: In this study, we aimed to develop a model to predict which patients with cirrhosis are at risk of developing overt hepatic encephalopathy (OHE). Using data from three units and including 426 outpatients with cirrhosis, we developed the AMMON-OHE model - comprising sex, diabetes, albumin, creatinine and ammonia levels - which demonstrated good predictive ability. The AMMON-OHE model performs better than PHES and CFF to predict the first episode of OHE in outpatients with cirrhosis. This model was validated in 267 and 381 patients from two independent liver units. The AMMON-OHE model is available online for clinical use.
引用
- Ballester MP, Tranah TH, Balcar L, et al. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis. J Hepatol. 2023. PMID: 37277075. doi:10.1016/j.jhep.2023.05.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。